Karyopharm Therapeutics Inc (KPTI)

8.13
0.08 0.97
NASDAQ : Health Care
Prev Close 8.21
Open 8.17
Day Low/High 8.00 / 8.22
52 Wk Low/High 4.83 / 23.59
Volume 44.29K
Avg Volume 183.00K
Exchange NASDAQ
Shares Outstanding 47.14M
Market Cap 384.18M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 19.7% Annualized Using Options

Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $9.34/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $7.50 strike, which has a bid at the time of this writing of 85 cents.

What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)

What to Watch During the Week: Cramer's 'Mad Money' Recap (Friday 7/7/17)

Earnings and Fed speakers are on tap in the next few days.

Karyopharm Therapeutics Stock Sees Short Interest Increase 13.3%

The most recent short interest data has been released for the 05/31/2017 settlement date, which shows a 351,835 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,991,079, an increase of 13.33% since 05/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Karyopharm Doses First Patient In Pivotal Phase 3 BOSTON Study Evaluating Selinexor In Patients With Relapsed/Refractory Multiple Myeloma

Enrollment Projected To Be Complete in 2018; Top-Line Data Expected in 2019

RSI Alert: Karyopharm Therapeutics (KPTI) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Karyopharm To Report First Quarter 2017 Financial Results On May 4, 2017

Conference Call Scheduled for Thursday, May 4, 2017 at 8:30 a.m. ET

Commit To Purchase Karyopharm Therapeutics At $7.50, Earn 15% Annualized Using Options

Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $11.72/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $7.50 strike, which has a bid at the time of this writing of 65 cents.

Six Stocks Spiking Up With Huge Volume

Six Stocks Spiking Up With Huge Volume

Here's a technical look at how to play six stocks trending higher with strong volume.

Short Interest Makes 14.6% Move For KPTI

The most recent short interest data has been released for the 03/31/2017 settlement date, which shows a 316,239 share increase in total short interest for Karyopharm Therapeutics Inc , to 2,483,391, an increase of 14.59% since 03/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Karyopharm And Medidata Expand Clinical Trial Partnership

Medidata (NASDAQ:MDSO) and clinical-stage pharmaceutical company Karyopharm Therapeutics (NASDAQ:KPTI) today announced an expanded partnership to bring novel machine-learning technology and targeted risk-based monitoring...

Karyopharm Announces Management Change

Karyopharm To Report Fourth Quarter And Year End 2016 Financial Results On March 16, 2017

Conference Call Scheduled for Thursday, March 16, 2017 at 8:30 a.m. ET

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Biotech Premarket Movers: Karyopharm, Lexicon, Prothena

Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.